FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥ 3 circulating tumour cells: the randomised phase III VISNÚ-1 trial Enrique Aranda, Jose Maria Viéitez, Auxiliadora Gómez-España, Silvia Gil Calle, Antonieta Salud-Salvia, Begoña Graña, Pilar Garcia. Alfonso, Fernando Rivera, Guillermo Alfonso Quintero-Aldana, Juan José Reina-Zoilo, Encarnación González-Flores, Mercedes Salgado Fernández, Carmen Guillén‑Ponce, Rocio Garcia-Carbonero, María José Safont, Adelaida La Casta Munoa, Beatriz García-Paredes, Rafael López, Javier Sastre, Eduardo Díaz-Rubio ESMO Open Volume 5 Issue 6 (January 2020) DOI: 10. 1136/esmoopen-2020 -000944 Copyright © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology. Terms and Conditions

Figure 1 ESMO Open 2020 5 DOI: (10. 1136/esmoopen-2020 -000944) Copyright © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology. Terms and Conditions

Figure 2 ESMO Open 2020 5 DOI: (10. 1136/esmoopen-2020 -000944) Copyright © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology. Terms and Conditions

Figure 3 ESMO Open 2020 5 DOI: (10. 1136/esmoopen-2020 -000944) Copyright © 2020 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology. Terms and Conditions